safinamide / Generic mfg. - LARVOL DELTA

Na V 1.7-dependent peripheral sensitization drives chronic pain in Parkinson's disease. (PubMed, bioRxiv) - "Safinamide is one of the few drugs reported to improve pain in PD, but the mechanism underlying this effect is unknown...Transcriptomic profiling of human PD DRGs revealed limited global transcriptional remodeling with selective alterations in genes associated with sensory neuron excitability. Together, these findings demonstrate that dopaminergic neurodegeneration initiated within the brain is sufficient to drive persistent peripheral sensory neuron dysfunction and identify CRMP2-dependent regulation of Na V 1.7 as a therapeutic target for Parkinsonian pain."

Journal • CNS Disorders • Immunology • Movement Disorders • Pain • Parkinson's Disease • CRMP

Design, synthesis and in silico evaluation of quinoline-indole chalcone hybrids for potential antibacterial, anticancer and antineurodegenerative applications. (PubMed, In Silico Pharmacol) - "The results indicated stronger binding interactions of 5f (- 11.86 kcal/mol) and 5g (- 9.71 kcal/mol) with antibacterial, 5d (- 11.89 kcal/mol) and 5h (- 11.72 kcal/mol) with anticancer and  5h (- 14.89 kcal/mol) and 5a (- 8.53 kcal/mol) with antineurodegenerative protein targets compared with the co-crystal ligands 07N and FKU for antibacterial (- 8.67 kcal/mol and - 10.95 kcal/mol) respectively, co-crystal ligand W2R (- 13.73 kcal/mol) and reference drug erlotinib (- 7.87 kcal/mol) for anticancer, safinamide (- 9.64 kcal/mol) and harmine (- 7.61 kcal/mol) for antineurodegenerative targets. These compounds showed comparable or stronger predicted binding affinities under the applied docking conditions. The online version contains supplementary material available at https://doi.org/10.1007/s40203-026-00735-z."

Journal • CNS Disorders • Oncology

Comparative efficacy and safety of Safinamide versus Opicapone in Japanese patients with Parkinson’s Disease and wearing-off: A matching-adjusted indirect comparison (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Safindream Safinamide as First Add On to Levodopa Improves Nonmotor Symptoms in Parkinson disease A Prospective Real World Study (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Consistent Motor Benefit of Safinamide across Clinically Relevant Subgroups in Japanese Patients with Parkinson’s Disease: A 24-Week Real-World Study (MDS Congress 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Safinamide dual molecular mechanisms: sodium channel and glutamate modulation as a translational rationale for neuropathic pain - A narrative review. (PubMed, Drug Metab Pers Ther) - "Although the existing clinical evidence outside the context of Parkinson's disease is still scarce, its pharmacodynamic characteristics make it possible to develop further studies in a variety of neuropathic pain syndromes using biomarker-based, randomized controlled trials."

Journal • Review • CNS Disorders • Inflammation • Movement Disorders • Musculoskeletal Pain • Neuralgia • Pain • NAV1

Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety. (PubMed, Sleep Med) - "pharmacological treatment of synucleinopathy-associated RBD remains supported by limited and heterogeneous evidence. Larger randomised trials using standardised clinical and vPSG outcomes are needed to clarify efficacy and safety."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Psychiatry • Sleep Disorder

SAVE PAIN: Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor Fluctuations (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Universita di Verona

New P3 trial • CNS Disorders • Movement Disorders • Pain • Parkinson's Disease • COMT

Daturaolone from Datura metel L. Inhibits acetylcholinesterase and monoamine oxidase B. (PubMed, Nat Prod Res) - "While no significant inhibition was detected towards BuChE, daturaolone inhibited AChE (IC50 = 45.06 ± 1.80 µM), even if with lower potency if compared to the positive control donepezil (IC50 = 0.047 ± 0.001 µM). Concerning MAO-B, daturaolone displayed an IC50 value of 28.04 ± 1.68 µM, higher of that of positive control safinamide (IC50 = 0.027 ± 0.001 µM). Molecular docking was used to study the binding to the catalytic sites of the macromolecular targets, while ligand-based studies predicted low-affinity interactions with protein phosphatases, androgen receptor, and β-secretase 1, along with limited drug-likeness."

Journal • CNS Disorders • Pain • AR

Add-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study. (PubMed, J Neural Transm (Vienna)) - "However, baseline imbalances, small sample size, non-randomized treatment allocation, and limitations in outcome assessment preclude conclusions regarding comparative treatment efficacy. These findings should be interpreted as preliminary and hypothesis-generating."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

A successful switch from rasagiline to safinamide in a 49-year-old female with early-onset Parkinson's disease: a case report and review of literature. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The case of a 49 year-old female patient with early-onset Parkinson's disease who was transitioned from 1 mg rasagiline to 50 mg safinamide with a three-day washout period is described; afterwards, we review the relevant literature and current recommendations. We believe this paper will be valuable to clinicians and researchers managing such scenarios, and perhaps motivate further larger sample size studies, or help inform best practices in the treatment of Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

SAFIN-DREAM: Real-World Effectiveness of Safinamide on Non-Motor Symptoms as First Add-On Therapy to Levodopa. (EAN 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence

Application of In Silico QSAR and Molecular Docking Studies to a Series of Xanthine-Based Analogues and Design, Synthesis and Pharmacological Evaluation of Identified New Potential Selective MAO-B Inhibitors. (PubMed, Pharmaceuticals (Basel)) - " Docking and MM-GBSA identified Jas6 and Jas7 as the most stable MAO-B binders, with binding free energies approaching those of safinamide...At 100 µM, the series produced mild but significant pro-oxidant and cytotoxic effects when applied alone, yet under oxidative stress all compounds, especially Jas2 and Jas6, markedly preserved synaptosomal and mitochondrial viability, maintained glutathione levels, and reduced malondialdehyde production. The caffeine-based semi- and thiosemicarbazides, particularly Jas2 and Jas6, emerge as promising selective MAO-B inhibitors with pronounced antioxidant and neuroprotective activity, supporting their further optimization as multitarget candidates for neurodegenerative disorders such as Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

A dual timeline of safinamide effects in Parkinson's disease: mechanistic rationale and clinical implications. (PubMed, Front Neurol) - "On the basis of these pharmacological characteristics and clinical observations, a phenotype-oriented approach to patient selection for safinamide therapy may be considered. In addition, recognizing the potential for a dual timeline of therapeutic effects may help clinicians guide patients' expectations of treatment and interpret treatment response, as well as optimizing follow-up strategies in routine clinical practice."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

SSY Group Obtains NMPA Approval For Safinamide Mesylate Tablets (TradingView) - "OBTAINS NMPA APPROVAL FOR PROCATEROL HYDROCHLORIDE INHALATION SOLUTION"

China approval • Asthma • Parkinson's Disease • Respiratory Diseases

Combination therapy of levodopa with safinamide is more effective than with rasagiline and zonisamide in Asian Parkinson's disease patients with motor fluctuations: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, J Neurol) - "The findings suggest that levodopa in combination with safinamide 100 mg is more efficacious than combinations with rasagiline 1 mg or zonisamide 25 mg for alleviating motor fluctuations and improving motor symptoms in Asian PD patients, and shows a more favourable (though not statistically significant) trend compared with zonisamide 50 mg."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson's Disease. (PubMed, Sci Rep) - "Dialysis experiments confirmed its reversible inhibition profile, comparable to the reference drug Safinamide...Molecular docking showed stabilization of MAO-B via π-π stacking interactions with Tyr326 and Tyr398, and molecular dynamics simulations further confirmed stable binding of BF2 within the MAO-B active site. Overall, BF2 emerged as a potent, selective, and reversible MAO-B inhibitor, warranting for further investigation."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Marked Improvement of Sialorrhea with Safinamide in Parkinson's Disease: A Case Series. (PubMed, Mov Disord) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Long-term safety and efficacy of safinamide in PD: Dose-based analysis of a phase III study (JSNE 2026) - No abstract available

Clinical • P3 data • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors. (PubMed, J Neural Transm (Vienna)) - "All ADD-ON therapies showed comparable treatment stability and tolerability. No statistically significant sex-related differences were observed, although a trend toward more frequent therapy modifications was found in female patients."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

In Vivo Electrochemical Monitoring of Safinamide Pharmacokinetics in the Brain Explores Its Correlation With Vision-Related Neuronal Activity. (PubMed, Adv Sci (Weinh)) - "This tight temporal correlation suggests that transient inhibition of vision-related neuronal activity may be directly associated with SAF concentration at the site. Overall, our study establishes an electrochemical approach enabling rapid, selective, and real-time drug monitoring in the living brain, offering a powerful tool to promote mechanistic studies of CNS drug action and safety."

Journal • PK/PD data • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Diplopia possibly induced by safinamide in parkinson's disease. (PubMed, Acta Neurol Belg) - No abstract available

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

The Safety and Efficacy of Monoamine Oxidase-B Inhibitors as Add-on Therapy to Dopamine Agonists for the Treatment of Parkinson’s Disease: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Background Parkinson's disease (PD) is a neurodegenerative disease, treated with carbidopa/levodopa or a dopamine agonist...They can be irreversible (selegiline and rasagiline) or reversible (safinamide)...Conclusions Selegiline (10mg/day) and safinamide (100mg) offer good therapeutic benefit as add-on therapy for PD. However, safinamide (100mg) has a relatively better safety profile as compared to selegiline (10mg/day). Further research should emphasize on long-term effects of these drugs through longitudinal studies focusing on patient-reported outcomes."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Sex Differences in Levodopa-Sparing Effect of Safinamide: Post-hoc Findings from a Multicenter, Longitudinal, Case-Control Study. (PubMed, Mov Disord Clin Pract) - "Safinamide 100 mg provides a larger levodopa-sparing effect in women, supporting sex-specific optimization of dopaminergic therapy in PD management."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Drug repurposing for disease-modifying effects in multiple system atrophy. (PubMed, Transl Neurodegener) - "We focus on agents targeting key pathogenic mechanisms in MSA-including α-synuclein aggregation (e.g., sirolimus/rapamycin, rifampicin, lithium, nilotinib, epigallocatechin gallate), neuroinflammation (e.g., minocycline, intravenous immunoglobulin), mitochondrial dysfunction and excitotoxicity (e.g., ubiquinol, rasagiline, safinamide, riluzole), and impaired neurotrophic support (e.g., fluoxetine/selective serotonin reuptake inhibitors, insulin, exendin-4). Nonetheless, ongoing studies and emerging approaches such as combination therapies hold promise. Continued exploration of repurposed therapies, along with improved trial design and biomarker development, is warranted to finally achieve a disease-modifying treatment for MSA."

Journal • Review • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Multiple System Atrophy